Port Delivery System With Ranibizumab vs Monitoring in Nonproliferative Diabetic Retinopathy Without Macular Edema
Sign Up to like & getrecommendations! Published in 2025 at "JAMA Ophthalmology"
DOI: 10.1001/jamaophthalmol.2025.0001
Abstract: Key Points Question Does the Port Delivery System (PDS) with ranibizumab, 100 mg/mL, refilled every 36 weeks, improve Diabetic Retinopathy Severity Scale (DRSS) levels in patients with nonproliferative diabetic retinopathy without center-involved diabetic macular edema… read more here.
Keywords: retinopathy; nonproliferative diabetic; delivery system; retinopathy without ... See more keywords